Improved mealtime treatment of diabetes mellitus using an insulin analogue

James H. Anderson, Rocco L. Brunelle, Veikko A. Koivisto, Michael E. Trautmann, Louis Vignati, Richard DiMarchi, D. P. Cameron, D. K. Yeu, P. Zimmet, J. P. Lauvaux, L. F. Van Gaal, J. L. Chiasson, I. M. Fettes, M. H. Tan, E. L. Toth, V. A. Koivisto, B. Charbonnel, J. L. Selam, M. Haslbeck, B. Schulze-Schleppinghoff & 34 others A. Karasik, H. J. Hazenberg, L. G. Van Doom, F. B. Bonnici, S. Hough, W. F. Mollentze, R. Moore, M. A. Omar, L. I. Robertson, R. J. Van Rooyen, A. De Leiva, A. Jara, J. A. Vazquez, S. Arslanian, E. J. Bastyr, R. M. Bergenstal, L. Blonde, P. A. Boyce, H. P. Chase, D. H. Clarke, J. Davidson, A. Garber, R. B. Goldberg, R. A. Guthrie, R. K. Mayfield, M. C. Mengel, M. J. Prince, M. L. Reeves, J. L. Rosenzweig, D. S. Schade, J. S. Soeldner, M. L. Spencer, F. W. Whitehouse, B. R. Zimmerman

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

The absorption of regular human insulin from subcutaneous injection sites is delayed due to the self-association of insulin to multimeric forms. The insulin analogue insulin lispro has a weak self-association and a fast absorption rate. We examined the safety and efficacy of insulin lispro in the premeal treatment of patients with diabetes mellitus. A 12-month study was performed in 336 patients with insulin-dependent diabetes mellitus (IDDM) and 295 patients with non-insulin-dependent diabetes mellitus (NIDDM). The patients were randomized to inject either regular human insulin 30 to 45 minutes before eating, or insulin lispro immediately before each meal, in addition to basal insulin. The postprandial rise in serum glucose was lower in patients receiving insulin lispro than in those receiving regular human insulin therapy. At end point, the increment was significantly lower at 1 hour (35%) and at 2 hours (64%) after the meal in IDDM patients; in NIDDM patients, the increment was nonsignificantly lower at 1 hour (19%) and significantly lower at 2 hours (48%). IDDM patients receiving insulin lispro achieved significantly lower glycated hemoglobin (HbA(1c)) levels in patients receiving regular human insulin (8.1% vs 8.3%). In NIDDM patients, HbA(1c) levels decreased equally in both treatment groups. Due to its fast absorption rate, insulin lispro improves postprandial control in diabetes. Insulin lispro can be considered one step toward optimal insulin therapy and improved patient convenience.

LanguageEnglish
Pages62-72
Number of pages11
JournalClinical Therapeutics
Volume19
Issue number1
DOIs
Publication statusPublished - 1 Jan 1997
Externally publishedYes

Keywords

  • diabetes mellitus
  • insulin analogue
  • insulin lispro
  • insulin therapy
  • postprandial control

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Anderson, J. H., Brunelle, R. L., Koivisto, V. A., Trautmann, M. E., Vignati, L., DiMarchi, R., ... Zimmerman, B. R. (1997). Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clinical Therapeutics, 19(1), 62-72. https://doi.org/10.1016/S0149-2918(97)80073-2
Anderson, James H. ; Brunelle, Rocco L. ; Koivisto, Veikko A. ; Trautmann, Michael E. ; Vignati, Louis ; DiMarchi, Richard ; Cameron, D. P. ; Yeu, D. K. ; Zimmet, P. ; Lauvaux, J. P. ; Van Gaal, L. F. ; Chiasson, J. L. ; Fettes, I. M. ; Tan, M. H. ; Toth, E. L. ; Koivisto, V. A. ; Charbonnel, B. ; Selam, J. L. ; Haslbeck, M. ; Schulze-Schleppinghoff, B. ; Karasik, A. ; Hazenberg, H. J. ; Van Doom, L. G. ; Bonnici, F. B. ; Hough, S. ; Mollentze, W. F. ; Moore, R. ; Omar, M. A. ; Robertson, L. I. ; Van Rooyen, R. J. ; De Leiva, A. ; Jara, A. ; Vazquez, J. A. ; Arslanian, S. ; Bastyr, E. J. ; Bergenstal, R. M. ; Blonde, L. ; Boyce, P. A. ; Chase, H. P. ; Clarke, D. H. ; Davidson, J. ; Garber, A. ; Goldberg, R. B. ; Guthrie, R. A. ; Mayfield, R. K. ; Mengel, M. C. ; Prince, M. J. ; Reeves, M. L. ; Rosenzweig, J. L. ; Schade, D. S. ; Soeldner, J. S. ; Spencer, M. L. ; Whitehouse, F. W. ; Zimmerman, B. R. / Improved mealtime treatment of diabetes mellitus using an insulin analogue. In: Clinical Therapeutics. 1997 ; Vol. 19, No. 1. pp. 62-72.
@article{380a396e13d240e087939e102ae9fda4,
title = "Improved mealtime treatment of diabetes mellitus using an insulin analogue",
abstract = "The absorption of regular human insulin from subcutaneous injection sites is delayed due to the self-association of insulin to multimeric forms. The insulin analogue insulin lispro has a weak self-association and a fast absorption rate. We examined the safety and efficacy of insulin lispro in the premeal treatment of patients with diabetes mellitus. A 12-month study was performed in 336 patients with insulin-dependent diabetes mellitus (IDDM) and 295 patients with non-insulin-dependent diabetes mellitus (NIDDM). The patients were randomized to inject either regular human insulin 30 to 45 minutes before eating, or insulin lispro immediately before each meal, in addition to basal insulin. The postprandial rise in serum glucose was lower in patients receiving insulin lispro than in those receiving regular human insulin therapy. At end point, the increment was significantly lower at 1 hour (35{\%}) and at 2 hours (64{\%}) after the meal in IDDM patients; in NIDDM patients, the increment was nonsignificantly lower at 1 hour (19{\%}) and significantly lower at 2 hours (48{\%}). IDDM patients receiving insulin lispro achieved significantly lower glycated hemoglobin (HbA(1c)) levels in patients receiving regular human insulin (8.1{\%} vs 8.3{\%}). In NIDDM patients, HbA(1c) levels decreased equally in both treatment groups. Due to its fast absorption rate, insulin lispro improves postprandial control in diabetes. Insulin lispro can be considered one step toward optimal insulin therapy and improved patient convenience.",
keywords = "diabetes mellitus, insulin analogue, insulin lispro, insulin therapy, postprandial control",
author = "Anderson, {James H.} and Brunelle, {Rocco L.} and Koivisto, {Veikko A.} and Trautmann, {Michael E.} and Louis Vignati and Richard DiMarchi and Cameron, {D. P.} and Yeu, {D. K.} and P. Zimmet and Lauvaux, {J. P.} and {Van Gaal}, {L. F.} and Chiasson, {J. L.} and Fettes, {I. M.} and Tan, {M. H.} and Toth, {E. L.} and Koivisto, {V. A.} and B. Charbonnel and Selam, {J. L.} and M. Haslbeck and B. Schulze-Schleppinghoff and A. Karasik and Hazenberg, {H. J.} and {Van Doom}, {L. G.} and Bonnici, {F. B.} and S. Hough and Mollentze, {W. F.} and R. Moore and Omar, {M. A.} and Robertson, {L. I.} and {Van Rooyen}, {R. J.} and {De Leiva}, A. and A. Jara and Vazquez, {J. A.} and S. Arslanian and Bastyr, {E. J.} and Bergenstal, {R. M.} and L. Blonde and Boyce, {P. A.} and Chase, {H. P.} and Clarke, {D. H.} and J. Davidson and A. Garber and Goldberg, {R. B.} and Guthrie, {R. A.} and Mayfield, {R. K.} and Mengel, {M. C.} and Prince, {M. J.} and Reeves, {M. L.} and Rosenzweig, {J. L.} and Schade, {D. S.} and Soeldner, {J. S.} and Spencer, {M. L.} and Whitehouse, {F. W.} and Zimmerman, {B. R.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1016/S0149-2918(97)80073-2",
language = "English",
volume = "19",
pages = "62--72",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "1",

}

Anderson, JH, Brunelle, RL, Koivisto, VA, Trautmann, ME, Vignati, L, DiMarchi, R, Cameron, DP, Yeu, DK, Zimmet, P, Lauvaux, JP, Van Gaal, LF, Chiasson, JL, Fettes, IM, Tan, MH, Toth, EL, Koivisto, VA, Charbonnel, B, Selam, JL, Haslbeck, M, Schulze-Schleppinghoff, B, Karasik, A, Hazenberg, HJ, Van Doom, LG, Bonnici, FB, Hough, S, Mollentze, WF, Moore, R, Omar, MA, Robertson, LI, Van Rooyen, RJ, De Leiva, A, Jara, A, Vazquez, JA, Arslanian, S, Bastyr, EJ, Bergenstal, RM, Blonde, L, Boyce, PA, Chase, HP, Clarke, DH, Davidson, J, Garber, A, Goldberg, RB, Guthrie, RA, Mayfield, RK, Mengel, MC, Prince, MJ, Reeves, ML, Rosenzweig, JL, Schade, DS, Soeldner, JS, Spencer, ML, Whitehouse, FW & Zimmerman, BR 1997, 'Improved mealtime treatment of diabetes mellitus using an insulin analogue', Clinical Therapeutics, vol. 19, no. 1, pp. 62-72. https://doi.org/10.1016/S0149-2918(97)80073-2

Improved mealtime treatment of diabetes mellitus using an insulin analogue. / Anderson, James H.; Brunelle, Rocco L.; Koivisto, Veikko A.; Trautmann, Michael E.; Vignati, Louis; DiMarchi, Richard; Cameron, D. P.; Yeu, D. K.; Zimmet, P.; Lauvaux, J. P.; Van Gaal, L. F.; Chiasson, J. L.; Fettes, I. M.; Tan, M. H.; Toth, E. L.; Koivisto, V. A.; Charbonnel, B.; Selam, J. L.; Haslbeck, M.; Schulze-Schleppinghoff, B.; Karasik, A.; Hazenberg, H. J.; Van Doom, L. G.; Bonnici, F. B.; Hough, S.; Mollentze, W. F.; Moore, R.; Omar, M. A.; Robertson, L. I.; Van Rooyen, R. J.; De Leiva, A.; Jara, A.; Vazquez, J. A.; Arslanian, S.; Bastyr, E. J.; Bergenstal, R. M.; Blonde, L.; Boyce, P. A.; Chase, H. P.; Clarke, D. H.; Davidson, J.; Garber, A.; Goldberg, R. B.; Guthrie, R. A.; Mayfield, R. K.; Mengel, M. C.; Prince, M. J.; Reeves, M. L.; Rosenzweig, J. L.; Schade, D. S.; Soeldner, J. S.; Spencer, M. L.; Whitehouse, F. W.; Zimmerman, B. R.

In: Clinical Therapeutics, Vol. 19, No. 1, 01.01.1997, p. 62-72.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Improved mealtime treatment of diabetes mellitus using an insulin analogue

AU - Anderson, James H.

AU - Brunelle, Rocco L.

AU - Koivisto, Veikko A.

AU - Trautmann, Michael E.

AU - Vignati, Louis

AU - DiMarchi, Richard

AU - Cameron, D. P.

AU - Yeu, D. K.

AU - Zimmet, P.

AU - Lauvaux, J. P.

AU - Van Gaal, L. F.

AU - Chiasson, J. L.

AU - Fettes, I. M.

AU - Tan, M. H.

AU - Toth, E. L.

AU - Koivisto, V. A.

AU - Charbonnel, B.

AU - Selam, J. L.

AU - Haslbeck, M.

AU - Schulze-Schleppinghoff, B.

AU - Karasik, A.

AU - Hazenberg, H. J.

AU - Van Doom, L. G.

AU - Bonnici, F. B.

AU - Hough, S.

AU - Mollentze, W. F.

AU - Moore, R.

AU - Omar, M. A.

AU - Robertson, L. I.

AU - Van Rooyen, R. J.

AU - De Leiva, A.

AU - Jara, A.

AU - Vazquez, J. A.

AU - Arslanian, S.

AU - Bastyr, E. J.

AU - Bergenstal, R. M.

AU - Blonde, L.

AU - Boyce, P. A.

AU - Chase, H. P.

AU - Clarke, D. H.

AU - Davidson, J.

AU - Garber, A.

AU - Goldberg, R. B.

AU - Guthrie, R. A.

AU - Mayfield, R. K.

AU - Mengel, M. C.

AU - Prince, M. J.

AU - Reeves, M. L.

AU - Rosenzweig, J. L.

AU - Schade, D. S.

AU - Soeldner, J. S.

AU - Spencer, M. L.

AU - Whitehouse, F. W.

AU - Zimmerman, B. R.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - The absorption of regular human insulin from subcutaneous injection sites is delayed due to the self-association of insulin to multimeric forms. The insulin analogue insulin lispro has a weak self-association and a fast absorption rate. We examined the safety and efficacy of insulin lispro in the premeal treatment of patients with diabetes mellitus. A 12-month study was performed in 336 patients with insulin-dependent diabetes mellitus (IDDM) and 295 patients with non-insulin-dependent diabetes mellitus (NIDDM). The patients were randomized to inject either regular human insulin 30 to 45 minutes before eating, or insulin lispro immediately before each meal, in addition to basal insulin. The postprandial rise in serum glucose was lower in patients receiving insulin lispro than in those receiving regular human insulin therapy. At end point, the increment was significantly lower at 1 hour (35%) and at 2 hours (64%) after the meal in IDDM patients; in NIDDM patients, the increment was nonsignificantly lower at 1 hour (19%) and significantly lower at 2 hours (48%). IDDM patients receiving insulin lispro achieved significantly lower glycated hemoglobin (HbA(1c)) levels in patients receiving regular human insulin (8.1% vs 8.3%). In NIDDM patients, HbA(1c) levels decreased equally in both treatment groups. Due to its fast absorption rate, insulin lispro improves postprandial control in diabetes. Insulin lispro can be considered one step toward optimal insulin therapy and improved patient convenience.

AB - The absorption of regular human insulin from subcutaneous injection sites is delayed due to the self-association of insulin to multimeric forms. The insulin analogue insulin lispro has a weak self-association and a fast absorption rate. We examined the safety and efficacy of insulin lispro in the premeal treatment of patients with diabetes mellitus. A 12-month study was performed in 336 patients with insulin-dependent diabetes mellitus (IDDM) and 295 patients with non-insulin-dependent diabetes mellitus (NIDDM). The patients were randomized to inject either regular human insulin 30 to 45 minutes before eating, or insulin lispro immediately before each meal, in addition to basal insulin. The postprandial rise in serum glucose was lower in patients receiving insulin lispro than in those receiving regular human insulin therapy. At end point, the increment was significantly lower at 1 hour (35%) and at 2 hours (64%) after the meal in IDDM patients; in NIDDM patients, the increment was nonsignificantly lower at 1 hour (19%) and significantly lower at 2 hours (48%). IDDM patients receiving insulin lispro achieved significantly lower glycated hemoglobin (HbA(1c)) levels in patients receiving regular human insulin (8.1% vs 8.3%). In NIDDM patients, HbA(1c) levels decreased equally in both treatment groups. Due to its fast absorption rate, insulin lispro improves postprandial control in diabetes. Insulin lispro can be considered one step toward optimal insulin therapy and improved patient convenience.

KW - diabetes mellitus

KW - insulin analogue

KW - insulin lispro

KW - insulin therapy

KW - postprandial control

UR - http://www.scopus.com/inward/record.url?scp=8244260603&partnerID=8YFLogxK

U2 - 10.1016/S0149-2918(97)80073-2

DO - 10.1016/S0149-2918(97)80073-2

M3 - Article

VL - 19

SP - 62

EP - 72

JO - Clinical Therapeutics

T2 - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 1

ER -

Anderson JH, Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R et al. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clinical Therapeutics. 1997 Jan 1;19(1):62-72. https://doi.org/10.1016/S0149-2918(97)80073-2